Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

Jithma P. Abeykoon; Saurabh Zanwar; Angela Dispenzieri; Morie A. Gertz; Nelson Leung; Taxiarchis Kourelis; Wilson Gonsalves; Eli Muchtar; David Dingli; Martha Q. Lacy; Suzanne R. Hayman; Francis Buadi; Rahma Warsame; Robert A. Kyle; Vincent Rajkumar; Shaji Kumar; Prashant Kapoor

doi:10.1038/s41375-018-0262-2

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

Jithma P. Abeykoon, Saurabh Zanwar, Angela Dispenzieri, Morie A. Gertz, Nelson Leung, Taxiarchis Kourelis, Wilson Gonsalves, Eli Muchtar, David Dingli, Martha Q. Lacy, Suzanne R. Hayman, Francis Buadi, Rahma Warsame, Robert A. Kyle, Vincent Rajkumar, Shaji Kumar, Prashant Kapoor

Hematology

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Original language	English (US)
Pages (from-to)	531-536
Number of pages	6
Journal	Leukemia
Volume	33
Issue number	2
DOIs	https://doi.org/10.1038/s41375-018-0262-2
State	Published - Feb 1 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-018-0262-2

Cite this

Abeykoon, J. P., Zanwar, S., Dispenzieri, A., Gertz, M. A., Leung, N., Kourelis, T., Gonsalves, W., Muchtar, E., Dingli, D., Lacy, M. Q., Hayman, S. R., Buadi, F., Warsame, R., Kyle, R. A., Rajkumar, V., Kumar, S., & Kapoor, P. (2019). Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia, 33(2), 531-536. https://doi.org/10.1038/s41375-018-0262-2

@article{d0b4f28114cf4e39bef1e376be490c7d,

title = "Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis",

author = "Abeykoon, {Jithma P.} and Saurabh Zanwar and Angela Dispenzieri and Gertz, {Morie A.} and Nelson Leung and Taxiarchis Kourelis and Wilson Gonsalves and Eli Muchtar and David Dingli and Lacy, {Martha Q.} and Hayman, {Suzanne R.} and Francis Buadi and Rahma Warsame and Kyle, {Robert A.} and Vincent Rajkumar and Shaji Kumar and Prashant Kapoor",

note = "Funding Information: Conflict of interest Dr. Gertz has received funding from Amgen, Prothena, Annexon, Appellis, Johnson and Johnson and Celgene. Dr. Dispenzieri has received research funding from Jannsen, Takeda, Celgene, Pfizer, Alnylam, Prothena, and GSK and serves on the advisory board for Takeda and Intellia. Dr. Kumar received research grants for clinical trials from Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen. Dr. Leung serves on the advisory board for Takeda and Prothena. Dr. Kapoor is principal investigator on studies for which Mayo Clinic receives funding from Takeda, Sanofi, and Amgen. The remaining authors declare no conflicts of interest. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = feb,

day = "1",

doi = "10.1038/s41375-018-0262-2",

language = "English (US)",

volume = "33",

pages = "531--536",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

AU - Abeykoon, Jithma P.

AU - Zanwar, Saurabh

AU - Dispenzieri, Angela

AU - Gertz, Morie A.

AU - Leung, Nelson

AU - Kourelis, Taxiarchis

AU - Gonsalves, Wilson

AU - Muchtar, Eli

AU - Dingli, David

AU - Lacy, Martha Q.

AU - Hayman, Suzanne R.

AU - Buadi, Francis

AU - Warsame, Rahma

AU - Kyle, Robert A.

AU - Rajkumar, Vincent

AU - Kumar, Shaji

AU - Kapoor, Prashant

N1 - Funding Information: Conflict of interest Dr. Gertz has received funding from Amgen, Prothena, Annexon, Appellis, Johnson and Johnson and Celgene. Dr. Dispenzieri has received research funding from Jannsen, Takeda, Celgene, Pfizer, Alnylam, Prothena, and GSK and serves on the advisory board for Takeda and Intellia. Dr. Kumar received research grants for clinical trials from Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen. Dr. Leung serves on the advisory board for Takeda and Prothena. Dr. Kapoor is principal investigator on studies for which Mayo Clinic receives funding from Takeda, Sanofi, and Amgen. The remaining authors declare no conflicts of interest. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/2/1

Y1 - 2019/2/1

UR - http://www.scopus.com/inward/record.url?scp=85054421339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054421339&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0262-2

DO - 10.1038/s41375-018-0262-2

M3 - Article

C2 - 30267007

AN - SCOPUS:85054421339

SN - 0887-6924

VL - 33

SP - 531

EP - 536

JO - Leukemia

JF - Leukemia

IS - 2

ER -

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this